21st.BIO files EU Novel Food application for animal-free BLG

Danish precision fermentation firm 21st.BIO has submitted a Novel Food application for beta‑lactoglobulin (BLG) and is urging faster EU approval for nature‑identical proteins.

21st.BIO files EU Novel Food application for animal‑free BLG Danish precision fermentation firm 21st.BIO has submitted an EU Novel Food application for BLG Essential+, its production technology for beta‑loglobulin (BLG), the main protein in whey. With the filing, the Copenhagen‑based company is asking European regulators for a faster approval route for well‑characterized, nature‑identical proteins made with host strains that already have a record of safe use. Mycotoxin‑Free Production Platform BLG Essential+ is produced with Aspergillus oryzae, the fungus used for centuries to make soy sauce and miso. Danish biosolutions company Novonesis developed the production platform over several decades and licenses part of it to 21st.BIO, which has developed it further for food protein production. A 2025 peer‑reviewed paper in Applied Microbiology and Biotechnology described the lineage as the first mycotoxin‑free A. oryzae line for industrial production of alternative and novel proteins. According to the study, the strains lack known mycotoxin biosynthesis pathways examined, and their penicillin G gene cluster has been inactivated. When 21st.BIO first announced the findings in April 2025, it already argued that the work should speed up approvals in Europe. “This is a well‑characterized production platform with consumer safety designed into the strain. Advanced genome analyses allow regulators to assess safety at strain level with far greater precision, and for proven platforms producing proteins that match those found in nature, the regulatory requirements should be lower and the safety evaluation more straightforward… and faster,” said José Arnau, Chief of Strain Engineering and Regulatory Affairs at 21st.BIO and co‑author of the study. Path to Faster EU Approval According to source 1, the EU dossier took years of scientific and procedural work and considerable investment, and the length of the approval process that follows makes it hard for producers to plan facilities and launches in Europe. The pathway 21st.BIO proposes would keep Europe’s current safety standards and give applicants a clearer timetable. Approval would bring investment in fermentation plants across Europe, creating jobs for scientists, operators and technicians and work for equipment manufacturers and process‑design firms. “Europe has the science, the companies and the industrial heritage in precision fermentation to lead the wave of healthy and nutritious food production. What Europe still needs is a home market that allows industrially proven technology to move from laboratories into fermentation factories built in Europe. A predictable, science‑based route to market can strengthen food resilience, attract industrial investment and ensure that European innovation is commercialized in Europe,” said CEO Thomas G. Schmidt. “This is not a choice between safety and speed. It is an opportunity to apply the best science to achieve both.” Clinical Use and Market Impact 21st.BIO is targeting high‑protein applications for BLG, including nutrition for older and ill people who need support with muscle maintenance and recovery, and for people on weight‑loss medication who want to keep muscle as they lose fat. The company also lists compact nutrition for people on the go and in conflict zones. “This is not a choice between safety and speed. It is an opportunity to apply the best science to achieve both. Europe can protect consumers, offer healthy and nutritious food options to Europeans, and offer nutritional self‑sufficiency, industrial production, skilled jobs and sustained technology leadership,” added Schmidt. BLG is the predominant protein in whey protein from milk, valued for its high‑quality amino‑acid profile and versatile functionality. BLG Essential+™ is a copy of the best protein in milk produced through precision fermentation. Source 3 notes that when approved by EFSA, 21st.BIO's BLG Essential+ can enable resource‑efficient milk protein production and sale in Europe using industrially proven precision fermentation technology. The filing follows regulatory approval for sales in the US, obtained in October 2025. Source 1 reports the US GRAS status was obtained in September 2024, while source 3 says October Biosystems. Approval of this technology can unlock significant investment and enable establishment of industrial production facilities across Europe, creating jobs for scientists, operators, technicians and skilled workers, while strengthening European equipment manufacturers, process‑design companies and scientific leadership.

Read source: Cultivated X